0000000000973009

AUTHOR

Alfonso Tortorella

showing 2 related works from this author

Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies

2020

AbstractEating disorders and substance use disorders frequently co-occur. Twin studies reveal shared genetic variance between liabilities to eating disorders and substance use, with the strongest associations between symptoms of bulimia nervosa (BN) and problem alcohol use (genetic correlation [rg], twin-based=0.23-0.53). We estimated the genetic correlation between eating disorder and substance use and disorder phenotypes using data from genome-wide association studies (GWAS). Four eating disorder phenotypes (anorexia nervosa [AN], AN with binge-eating, AN without binge-eating, and a BN factor score), and eight substance-use-related phenotypes (drinks per week, alcohol use disorder [AUD], …

Netherlands Twin Register (NTR)Alcoholism/geneticsSchizophrenia/genetics[SDV]Life Sciences [q-bio][SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthMedizinMedicine (miscellaneous)Genome-wide association studyAlcohol use disorderAnorexia nervosaLinkage Disequilibriumddc:616.89[SCCO]Cognitive science0302 clinical medicineRisk FactorsTobacco Use Disorder/geneticsSubstance-Related Disorders/genetics0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyFactors de risc en les malaltiesBulimia nervosaFeeding and Eating Disorders/geneticseating disorders; genetic correlation; substance useTobacco Use Disordergenetic correlation3. Good healthFenotip[SDV] Life Sciences [q-bio]Psychiatry and Mental healthAlcoholismEating disordersPhenotypeSchizophreniaDrinking of alcoholic beverageseating disorderConsum d'alcoholMajor depressive disorder/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingmedicine.symptomDepressive Disorder Major/geneticseating disorders genetic correlation substance useClinical psychologySubstance abuseRisk factors in diseasesSubstance-Related Disorderssubstance useeating disordersPolymorphism Single NucleotideArticleFeeding and Eating Disorders03 medical and health sciencesSDG 3 - Good Health and Well-beingmental disorders/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_GeneticsmedicineHumansTrastorns de la conducta alimentària030304 developmental biologyGenetic associationPharmacologyeating disorders ; genetic correlation ; substance useDepressive Disorder MajorBinge eatingbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/Neurosciencesubstance use.[SCCO] Cognitive sciencemedicine.diseaseComorbidityTwin study030227 psychiatryAbús de substàncies[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthSchizophreniabusinessGenètica030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyGenome-Wide Association Study
researchProduct

Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice

2019

Abstract Objectives To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. Methods Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. Results Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5…

Long actingMaleAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Psychiatry and Mental Health; Biological PsychiatryAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Treatment OutcomePersonalizedAripiprazole0302 clinical medicineRetrospective StudieDelayed-Action PreparationMaintenaMiddle AgedhumanitiesClinical PracticeTreatment OutcomeItalySchizophreniaPsychiatry and Mental HealthAripiprazoleFemaleBiological psychiatrymedicine.symptomManiaHumanmedicine.drugAntipsychotic AgentsAdultmedicine.medical_specialtyMedication AdherencePersistence03 medical and health scienceshealth services administrationInternal medicinemental disordersmedicineTreatment persistenceHumansBiological PsychiatryRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized;030227 psychiatryAntipsychotic AgentLong actingAdherenceDelayed-Action PreparationsSchizophreniabusiness030217 neurology & neurosurgery
researchProduct